MUFG Securities EMEA plc Buys 11,780 Shares of Amgen Inc. $AMGN

MUFG Securities EMEA plc lifted its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 114.3% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 22,085 shares of the medical research company’s stock after acquiring an additional 11,780 shares during the period. MUFG Securities EMEA plc’s holdings in Amgen were worth $7,229,000 as of its most recent SEC filing.

A number of other hedge funds also recently made changes to their positions in AMGN. High Note Wealth LLC grew its position in Amgen by 5.8% during the fourth quarter. High Note Wealth LLC now owns 508 shares of the medical research company’s stock valued at $166,000 after acquiring an additional 28 shares during the last quarter. West Family Investments Inc. lifted its holdings in shares of Amgen by 1.1% in the 3rd quarter. West Family Investments Inc. now owns 2,760 shares of the medical research company’s stock worth $779,000 after acquiring an additional 30 shares during the last quarter. Viawealth LLC lifted its holdings in shares of Amgen by 0.4% in the 3rd quarter. Viawealth LLC now owns 7,168 shares of the medical research company’s stock worth $2,023,000 after acquiring an additional 30 shares during the last quarter. LOM Asset Management Ltd boosted its stake in shares of Amgen by 1.2% in the 3rd quarter. LOM Asset Management Ltd now owns 2,554 shares of the medical research company’s stock valued at $721,000 after purchasing an additional 30 shares in the last quarter. Finally, Smith Salley Wealth Management boosted its stake in shares of Amgen by 0.3% in the 4th quarter. Smith Salley Wealth Management now owns 10,786 shares of the medical research company’s stock valued at $3,530,000 after purchasing an additional 30 shares in the last quarter. 76.50% of the stock is owned by institutional investors.

Amgen Stock Performance

Shares of AMGN opened at $336.79 on Monday. The stock has a market capitalization of $181.77 billion, a P/E ratio of 23.44, a PEG ratio of 3.38 and a beta of 0.42. The company has a quick ratio of 1.01, a current ratio of 1.26 and a debt-to-equity ratio of 5.65. The firm has a fifty day simple moving average of $342.53 and a two-hundred day simple moving average of $345.48. Amgen Inc. has a twelve month low of $267.83 and a twelve month high of $391.29.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings results on Thursday, April 30th. The medical research company reported $5.15 earnings per share for the quarter, beating the consensus estimate of $4.77 by $0.38. The business had revenue of $8.62 billion during the quarter, compared to analysts’ expectations of $8.58 billion. Amgen had a net margin of 20.96% and a return on equity of 137.41%. The firm’s revenue for the quarter was up 5.8% compared to the same quarter last year. During the same quarter in the prior year, the company posted $4.90 EPS. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. On average, research analysts anticipate that Amgen Inc. will post 22.37 EPS for the current year.

Amgen Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, June 5th. Investors of record on Friday, May 15th will be paid a $2.52 dividend. The ex-dividend date of this dividend is Friday, May 15th. This represents a $10.08 annualized dividend and a dividend yield of 3.0%. Amgen’s dividend payout ratio (DPR) is presently 70.15%.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on AMGN. The Goldman Sachs Group upped their price objective on shares of Amgen from $415.00 to $425.00 and gave the company a “buy” rating in a research note on Friday, May 1st. Wall Street Zen raised shares of Amgen from a “hold” rating to a “buy” rating in a research note on Saturday, May 23rd. Canaccord Genuity Group began coverage on shares of Amgen in a research note on Monday, April 20th. They issued a “hold” rating and a $366.00 price objective for the company. UBS Group upped their price objective on shares of Amgen from $390.00 to $400.00 and gave the company a “buy” rating in a research note on Monday, April 13th. Finally, Royal Bank Of Canada upped their price objective on shares of Amgen from $360.00 to $370.00 and gave the company an “outperform” rating in a research note on Tuesday, April 7th. Two research analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, fourteen have assigned a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat, Amgen has a consensus rating of “Hold” and an average target price of $355.19.

Insider Activity

In related news, SVP Nancy A. Grygiel sold 1,237 shares of the firm’s stock in a transaction dated Monday, May 4th. The stock was sold at an average price of $323.73, for a total value of $400,454.01. Following the sale, the senior vice president directly owned 7,009 shares of the company’s stock, valued at $2,269,023.57. This trade represents a 15.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 0.85% of the stock is owned by insiders.

Amgen Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.